MET gene amplification is observed in 2 to 4 percent of treatment-naïve NSCLC and in 5 to 20 percent of EGFR-mutated tumors that have acquired resistance to EGFR inhibitors. The gene discussed is MET; the disease is non-small cell lung carcinoma.